Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492068 | 1.00 | POLB (0.38) | POLBTSHRALOX5KCNQ3KCNQ2 | |
| SCHEMBL22492071 | 1.00 | POLB (0.38) | POLBTSHRALOX5KCNQ3KCNQ2 | |
| SCHEMBL22492099 | 0.81 | KCNQ3 (0.53) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492105 | 0.81 | KCNQ3 (0.53) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492104 | 0.81 | KCNQ3 (0.53) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492042 | 0.77 | KCNQ3 (0.41) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492040 | 0.77 | KCNQ3 (0.41) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492037 | 0.77 | KCNQ3 (0.41) | POLBTSHRKCNQ3KCNQ2KCNQ4 | |
| SCHEMBL22492132 | 0.76 | ALOX5 (0.41) | POLBTSHRALOX5KCNQ3KCNQ2 | |
| SCHEMBL22466324 | 0.74 | ALOX5 (0.48) | TSHRALOX5OPRK1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | LES LABORATOIRES SERVIER (FR) | 2022-05-17 | — | — | US | disclosed |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | LES LABORATOIRES SERVIER (FR) | 2020-12-31 | — | — | US | disclosed |
| EP-3717482-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Les Laboratoires Servier SAS (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332472-B2 | Substituted piperidines as inhibitors of ubiquitin specific protease 7 | USP7, PSMA7, PSMB7 | POLB 1500/4885TSHR 4124/4885ALOX5 4735/4885 |
| US-20200407363-A1 | NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | PSMB7, PSMA7, USP7 | POLB 1423/4885TSHR 4411/4885ALOX5 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.